Allergy Thera. Regulatory News (AGY)

2 July 2015

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Company to Host Key Allergy Conference

Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces that it is hosting the Eighth Annual Adjuvants in Allergy Conference in Amsterdam on the 2-4 July.

At the conference, Dr. Albert Roger Director of the Allergy Unit at Universitari Hospital Germans Trias Pujol, Badalona Spain, will present data from the Company's recent Acarovac efficacy study for the treatment against house dust mite allergy.  Acarovac has been Allergy Therapeutics strongest growing treatment in Spain this year and it is one of the Company's new generation of products developed to address the perennial allergy market with innovative and short-course therapies.

The conference provides an outstanding opportunity for scientific debate and dialogue amongst 200 specialists in respiratory diseases and allergology from all over Europe and America. New perspectives and innovations in allergy treatment will be presented by international key opinion leaders in order to initiate the process of global shared knowledge in these areas and ultimately lead to improvements in patient outcomes.

There is an exciting programme of topics to facilitate in-depth discussions, which include, the impact for allergists on changes to the climate and migration patterns, the distribution of pollen counts and their annual patterns, the generation and maintenance of allergen specific T-cell tolerance, options and strategies for primary and secondary prevention of atopy and asthma, and the dramatic increase in the prevalence of allergic diseases.

Manuel Llobet, Chief Executive Officer, commented:

"Allergy Therapeutics is proud to host the Eighth Annual Adjuvants in Allergy Conference, a highly scientific open forum to discuss allergy topics with expert key opinion leaders and allergists from around the world. The aim of the conference is to encourage the medical community to consider innovative solutions for patients suffering from allergies and we are excited to be at the forefront of these discussions."

For more information on the conference and a programme outline, please use the following link: http://www.allergytherapeutics.nl/files/2914/2167/1597/ATL_program.pdf.

-Ends-

For further information:

Note to editors

About Adjuvants in Allergy

Adjuvants in Allergy provides an outstanding opportunity for scientific debate and dialogue among 200 specialists in respiratory diseases and allergology from all over Europe and America. The purpose of this educational meeting is to highlight different diagnostic and therapeutic aspects as presented by expert key opinion leaders who will review the current state of knowledge in these areas.

New perspectives and innovations in allergy treatment will include:

· Significant changes to the climate and migration patterns present new therapeutic and diagnostic demands for the allergist. These changes, although global, particularly impact clinical care in Europe.

· The distribution of pollen counts and their annual patterns. This, together with services that provide personalised predictions for patients will be discussed. The future of allergic disease therapy will be explored through the latest scientific data including how environmental factors precipitate disease in people with inherited susceptibilities and how to enhance diagnostic accuracy via the recognition of environmental risk factors.

· Another important step forward in the allergy field is the generation and maintenance of allergen specific T-cell tolerance. The latest data on therapy induced changes to the innate immune system will be discussed together with a discussion of the efficacy and duration of therapy.

· The opportunity to achieve sustained disease modification will be explored and the importance of this research in clinical practice will be emphasised. The significant consequences of allergic disease on quality of life have driven research to understand how allergy vaccines might prevent the onset of allergic disease. This will be discussed in the context of the options and strategies for primary and secondary prevention of atopy and asthma.

· Additionally, the latest thinking on adjuvants that enhance the immune response will be explored. A major development in disease modifying agents which aim to restore the Th1 balance rather than Th2 has potential in therapy for allergic disease. Erika Jensen-Jarolim will provide a critical overview about aluminium used as an adjuvant in vaccination and immunotherapy. Thomas Kuendig will characterise the "ideal adjuvant", whereas two further presentations will focus on MPL - an adjuvant successfully introduce into immunotherapy by Allergy Therapeutics in 1999.

· Finally, one important aspect concerns the dramatic increase in the prevalence of allergic diseases. The hygiene hypothesis has now changed to the microbial exposure hypothesis, where exposure to microbes is closely linked to the development of the early immune system and allergic disease. The intestinal flora may contribute to allergic disease through its substantial effect on mucosal immunity. Based on findings that exposure to microbial flora early in life can change the Th1/Th2 balance towards a Th1 cell response, we will discuss how probiotics may be beneficial in preventing allergic disease.

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.